Take your pill at the same time every day in the order directed on your pill pack. Always refill and pick up your prescription before you finish your pill pack. Check with your pharmacist for your copay discount. Maximum savings limit applies; patient out-of-pocket expense will vary.
Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Another Birth Control Pill. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. You do not need to use a backup birth control method if you have sex. Take 2 pills on the day you remember and 2 pills the next day. Then continue taking 1 pill a day until you finish the pack.
Throw out the rest of the pill pack and start a new pack that same day. You may not have your period this month, but this is expected. However, if you miss your period 2 months in a row, call your healthcare provider because you might be pregnant. You could become pregnant if you have sex on the days when you missed pills or during the first 7 days after restarting your pills.
You MUST use a non-hormonal birth control method such as a condom and spermicide as a backup the next time you have sex and for the first 7 days after you restart your pills. Throw away the pills you missed. Keep taking 1 pill each day until the pack is empty. You do not need to use a backup method of birth control. Use a backup method of birth control any time you have sex. Keep taking 1 pill each day until you can reach your healthcare provider.
Who should not take Lo Loestrin Fe? What else should I know about taking Lo Loestrin Fe? What are the most serious risks of taking Lo Loestrin Fe? What are the possible side effects of Lo Loestrin Fe? A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives 15, The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions 15, If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization.
Since the immediate postpartum period is also associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breastfeed. Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events thrombotic and hemorrhagic strokes , although, in general, the risk is greatest among older greater than 35 years , hypertensive women who also smoke.
Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension The relative risk of hemorrhagic stroke is reported to be 1.
The attributable risk is also greater in older women 9. A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease A decline in serum high-density lipoproteins HDL has been reported with many progestational agents A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease.
Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestin and the nature of the progestin used in the contraceptives. The amount and activity of both hormones should be considered in the choice of an oral contraceptive. Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular oral contraceptive, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with the needs of the individual patient.
New acceptors of oral contraceptive agents should be started on preparations containing the lowest dose of estrogen which produces satisfactory results for the patient. There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing oral contraceptives persists for at least 9 years for women 40 to 49 years who had used oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small However, both studies were performed with oral contraceptive formulations containing 50 mcg or higher of estrogens.
One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages Table III. These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth.
The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 's--but not reported until However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling.
Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed Porter JB, Hunter J, Jick H, et al. Oral contraceptives and nonfatal vascular disease. Mortality among oral contraceptive users. The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women even with the newer low-dose formulations , there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception.
Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective.
Numerous epidemiological studies have been performed on the incidence of breast, endometrial, ovarian, and cervical cancer in women using oral contraceptives. Most of the studies on breast cancer and oral contraceptive use report that the use of oral contraceptives is not associated with an increase in the risk of developing breast cancer 42,44, Some studies have reported an increased risk of developing breast cancer in certain subgroups of oral contraceptive users, but the findings reported in these studies are not consistent 43,, Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.
In spite of many studies of the relationship between oral contraceptive use and breast and cervical cancers, a cause and effect relationship has not been established. Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States.
Indirect calculations have estimated the attributable risk to be in the range of 3. Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage 56, Studies from Britain have shown an increased risk of developing hepatocellular carcinoma in long-term greater than 8 years oral contraceptive users. However, these cancers are extremely rare in the U. There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives.
Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately. Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb reduction defects are concerned 61,62,64,65 , when taken inadvertently during early pregnancy.
The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period.
Oral contraceptive use should be discontinued if pregnancy is confirmed. Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens 66, More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens.
Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users Oral contraceptives containing greater than 75 mcg of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents 23, However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives.
A small proportion of women will have persistent hypertriglyceridemia while on the pill. An increase in blood pressure has been reported in women taking oral contraceptives 74 and this increase is more likely in older oral contraceptive users 75 and with continued use Data from the Royal College of General Practitioners 18 and subsequent randomized trials have shown that the incidence of hypertension increases with increasing concentrations of progestogens.
Women with a history of hypertension or hypertension-related diseases or renal disease 76 should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued.
For most women, elevated blood pressure will return to normal after stopping oral contraceptives 75 , and there is no difference in the occurrence of hypertension among ever and never users 74,76, The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause.
Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Non-hormonal causes should be considered, and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may solve the problem.
In the event of amenorrhea, pregnancy should be ruled out. Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent.
It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests.
In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care. Women who are being treated for hyperlipidemia should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult.
If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function.
Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention.
Women with a history of depression should be carefully observed and the drug discontinued if depression recurs to a serious degree. Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist. Rifampin: Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin.
A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin. Antibiotics: Pregnancy while taking oral contraceptives has been reported when the oral contraceptives were administered with antimicrobials such as ampicillin, tetracycline, and griseofulvin. However, clinical pharmacokinetic studies have not demonstrated any consistent effect of antibiotics other than rifampin on plasma concentrations of synthetic steroids.
Other: Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone. Oral contraceptive combinations containing ethinyl estradiol may inhibit the metabolism of other compounds. Increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives.
In addition, oral contraceptives may induce the conjugation of other compounds. Decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives.
Certain endocrine and liver function tests and blood components may be affected by oral contraceptives:. Pregnancy Category X. Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers, and a few adverse effects on the child have been reported, including jaundice and breast enlargement.
In addition, oral contraceptives, given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated.
There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed:.
The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:. The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted:. Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.
The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0. The tablet dispenser has been designed to make oral contraceptive dosing as easy and as convenient as possible.
The tablets are arranged in either three or four rows of seven tablets each, with the days of the week appearing on the tablet dispenser above the first row of tablets.
Note: Each tablet dispenser has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive days of the week sticker that corresponds to her starting day over the preprinted days.
Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen.
Two dosage regimens are described, one of which may be more convenient or suitable than the other for an individual patient. For the initial cycle of therapy, the patient begins her tablets according to the Day-1 Start or Sunday-Start regimen. With either regimen, the patient takes one tablet daily for 21 consecutive days followed by one week of no tablets. Tablets should be taken regularly with a meal or at bedtime. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule.
Menstruation usually begins two or three days, but may begin as late as the fourth or fifth day, after discontinuing medication. If spotting occurs while on the usual regimen of one tablet daily, the patient should continue medication without interruption. The possibility of ovulation occurring increases with each successive day that scheduled tablets are missed. While there is little likelihood of ovulation occurring if only one tablet is missed, the possibility of spotting or bleeding is increased.
This is particularly likely to occur if two or more consecutive tablets are missed. In the rare case of bleeding which resembles menstruation, the patient should be advised to discontinue medication and then begin taking tablets from a new tablet dispenser on the next Sunday or the first day Day 1 , depending on her regimen. Persistent bleeding which is not controlled by this method indicates the need for reexamination of the patient, at which time nonfunctional causes should be considered.
The ferrous fumarate tablets are present to facilitate ease of drug administration via a day regimen and do not serve any therapeutic purpose. Menstruation usually begins two or three days, but may begin as late as the fourth or fifth day, after the brown tablets have been started.
In any event, the next course of tablets should be started without interruption. If spotting occurs while the patient is taking light yellow or pink tablets, continue medication without interruption. If the patient forgets to take one or more light yellow or pink tablets, the following is suggested:. The possibility of ovulation occurring increases with each successive day that scheduled light yellow or pink tablets are missed.
While there is little likelihood of ovulation occurring if only one light yellow or pink tablet is missed, the possibility of spotting or bleeding is increased.
This is particularly likely to occur if two or more consecutive light yellow or pink tablets are missed. If the patient forgets to take any of the seven brown tablets in week four, those brown tablets that were missed are discarded and one brown tablet is taken each day until the pack is empty.
A back-up birth control method is not required during this time. A new pack of tablets should be started no later than the eighth day after the last light yellow or pink tablet was taken. In the rare case of bleeding which resembles menstruation, the patient should be advised to discontinue medication and then begin taking tablets from a new tablet dispenser on the next Sunday or the first day Day-1 , depending on her regimen.
After several months on treatment, bleeding may be reduced to a point of virtual absence. This reduced flow may occur as a result of medication, in which event it is not indicative of pregnancy.
Each card contains 21 light yellow, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and on the other side. NDC Each card contains 21 light yellow, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and on the other side and 7 brown, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and on the other side.
Each brown tablet contains 75 mg ferrous fumarate. Each card contains 21 pink, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and on the other side. Each card contains 21 pink, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and on the other side and 7 brown, round, flat-faced, beveled-edge, unscored tablets debossed with stylized b on one side and on the other side.
This product like all oral contraceptives is intended to prevent pregnancy. North Wales, PA For most women, oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy. For the majority of women, oral contraceptives can be taken safely.
But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability. The risks associated with taking oral contraceptives increase significantly if you:. You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding.
Women who use oral contraceptives are strongly advised not to smoke. Most side effects of the pill are not serious. The most common side effects are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness, and difficulty wearing contact lenses.
These side effects, especially nausea, vomiting, and breakthrough bleeding may subside within the first three months of use. The serious side effects of the pill occur very infrequently, especially if you are in good health and are young.
However, you should know that the following medical conditions have been associated with or made worse by the pill:. The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills.
Notify your doctor or healthcare provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics, may decrease oral contraceptive effectiveness. Most of the studies to date on breast cancer and pill use have found no increase in the risk of developing breast cancer, although some studies have reported an increased risk of developing breast cancer in certain groups of women.
However, some studies have found an increase in the risk of developing cancer of the cervix in women taking the pill, but this finding may be related to differences in sexual behavior or other factors not related to use of the pill. Therefore, there is insufficient evidence to rule out the possibility that the pill may cause cancer of the breast or cervix. Taking the pill provides some important non-contraceptive benefits.
These include less painful menstruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus.
Be sure to discuss any medical condition you may have with your healthcare provider. Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it.
You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your healthcare provider. It does not protect against transmission of HIV AIDS and other sexually transmitted diseases such as Chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis.
The tablets are arranged in either three or four rows of seven tablets each, with the days of the week appearing above the first row of tablets. Each light yellow tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each brown tablet contains 75 mg ferrous fumarate, and is intended to help you remember to take the tablets correctly.
These brown tablets are not intended to have any health benefit. To remove a tablet, press down on it with your thumb or finger. The tablet will drop through the back of the tablet dispenser. Do not press with your thumbnail, fingernail, or any other sharp object.
You have a choice of which day to start taking your first pack of pills. Decide with your doctor or clinic which is the best day for you. Pick a time of day which will be easy to remember.
Based on his or her assessment of your medical needs, your doctor or healthcare provider has prescribed this drug for you. Do not give this drug to anyone else. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible.
However, this leaflet is not a replacement for a careful discussion between you and your healthcare provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits.
You should also follow your healthcare provider's advice with regard to regular check-ups while you are on the pill. The chance of becoming pregnant increases with each missed pill during a menstrual cycle. In comparison, typical failure rates for other methods of birth control during the first year of use are as follows:. Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant.
You should also not use the pill if you have any of the following conditions:. Tell your healthcare provider if you have ever had any of these conditions. Your healthcare provider can recommend a safer method of birth control. Women with any of these conditions should be checked often by their healthcare provider if they choose to use oral contraceptives.
Also, be sure to inform your doctor or healthcare provider if you smoke or are on any medications. All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death.
An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table.
In the above table, the risk of death from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke.
It can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy 7 to 26 deaths per , women, depending on age. Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 deaths per , women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of deaths exceeds those for other methods of birth control.
The suggestion that women over 40 who don't smoke should not take oral contraceptives is based on information from older higher dose pills and on less selective use of pills than is practiced today.
An Advisory Committee of the FDA discussed this issue in and recommended that the benefits of oral contraceptive use by healthy, non-smoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest dose pill that is effective. If any of these adverse effects occur while you are taking oral contraceptives, call your doctor immediately:.
If failure does occur, the risk to the fetus is minimal. There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives.
It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill. Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children.
Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your healthcare provider or pharmacist. You should be reexamined at least once a year. Be sure to inform your healthcare provider if there is a family history of any of the conditions listed previously in this leaflet.
Be sure to keep all appointments with your healthcare provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use. Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills.
In addition to preventing pregnancy, use of oral contraceptives may provide certain benefits. They are:. If you want more information about birth control pills, ask your doctor or pharmacist. Your birth control pills may not be as effective if you miss any blue or white pills, especially if you miss the first few or the last few blue pills in a pack.
If you are not sure of what to do about the pills you have missed, you should call your healthcare provider. Use a backup method of birth control, such as a condom and spermicide, anytime you have sex, and keep taking 1 pill each day until you reach your healthcare provider. Yes, it's normal. Spotting, also called irregular bleeding or breakthrough bleeding, typically happens during the first few months of taking a new birth control pill.
It may take time for your body to adjust to the new hormone levels. If spotting still occurs after being on the pill for more than 6 months you should see your healthcare provider to make sure there isn't another underlying condition.
Lo Loestrin Fe is a prescription birth control pill used for the prevention of pregnancy. Do not use Lo Loestrin Fe if you smoke cigarettes and are over 35 years old. Treatment with Lo Loestrin Fe should be stopped if you have a blood clot, and at least 4 weeks before and through 2 weeks after major surgery.
You should not take Lo Loestrin Fe any earlier than 4 weeks after having a baby, or if you are breastfeeding. If you experience yellowing of the skin or eyes due to problems with your liver, you should stop taking Lo Loestrin Fe.
If you are pre-diabetic or diabetic, your doctor should monitor you while using Lo Loestrin Fe. Your doctor should evaluate you if you have any significant change in headaches or irregular menstrual bleeding. Lo Loestrin Fe increases the risk of serious conditions including blood clots, stroke, and heart attack. These can be life-threatening or lead to permanent disability. Check with your pharmacist for your copay discount.
Maximum savings limits apply; patient out-of-pocket expense will vary. This offer is not valid for use by patients enrolled in Medicare, Medicaid, or other federal or state programs including any state pharmaceutical assistance programs , or private indemnity or HMO insurance plans that reimburse you for the entire cost of your prescription drugs.
Patients may not use this offer if they are Medicare-eligible and enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees. This offer is not valid for cash-paying patients. Each card is valid for up to thirteen 13 prescription fills of a day supply each OR up to four 4 prescription fills of an day supply each.
This card is not transferable. The selling, purchasing, trading, or counterfeiting of this card is prohibited by law. This card has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified prescription. By redeeming this card, you acknowledge that you are an eligible patient and that you understand and agree to comply with the terms and conditions of this offer.
For questions about the program, including savings on mail order prescriptions, please call 1. When you redeem this card, you certify that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other government programs for this prescription.
Reimbursement will be received from Change Healthcare. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Lo Loestrin Fe norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets is a prescription birth control pill used for the prevention of pregnancy.
How well does Lo Loestrin Fe work?
0コメント